Savvy Trades and Investments

[abh3vt]

ANIP in with a good quarter. Another beat and raise for them. Similar management style to HALO in their earnings "management"; where they typically guide very conservatively to give themselves room to exceed expectations. They don't have anywhere near the pretax margins because they have a product mix that includes generics. Primarily US footprint, 10% of drugs they sell are imports; <5% from China.

Valuation: I could see them at 12-14x forward earnings, and I expect to see analysts raise their numbers soon. FY26 est look too low to me too.